Moreover, CD26/DPP-4 inhibitors have been assessed and investigated for their nephroprotective role in glycemic management to reduce the incidence of micro- or macroalbuminuria in type 2 diabetes patients [115,116,117]. Here, DPP4 is linked to type 2 diabetes mellitus.